Cochleates as nanoparticular drug carriers

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 349-366

  Zarif, Leila ^a  

^a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER;

DRUG DELIVERY;

EID: 84875924819     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0016     Document Type: Chapter

References (79)

1. Chien YW (1992) Novel drug delivery systems. Drugs and the Pharmaceutical Sciences, Vol. 50. Marcel Dekker: New York, NY.
2. Rathbone MJ, Hadgraft J and Michael SR (2003) Modified-release drug delivery technology. Drugs and the Pharmaceutical Sciences, Vol. 126. Marcel Dekker: New York, NY.
3. Charman WN (2000) Lipids, lipophilic drugs and oral delivery-some emerging concepts. J Pharm Sci 89:967-978.
4. Bowtle W (2000) Lipid formulations for oral drug delivery. Pharm Technol Eur 12(9):20-30.
5. Attwood D (1994) Microemulsions, in Kreutrer J (ed.) Colloidal Drug Delivery Systems. Marcel Dekker: New York, pp. 31-71.
6. Lawrence MJ (1996) Microemulsions as drug delivery vehicles. Curr Opin Colloid Interface Sci 1:826-832.
7. Pouton CW and Charman WN (1997) The potential of oily formulations for drug delivery to the gastrointestinal tract. Adv Drug Del Rev 25:1-2.
8. Muller RH, Mader K and Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery. A review of the state of the art. Eur J Pharm Biopharm 50:161-177.
9. Westesen K (2000) Novel lipid-based colloidal dispersions as potential drug administration systems, expectations and reality. Colloid Polym Sci 278:608-618.
10. Lamprecht A, Bouligand Y and Benoit JP (2002) New lipid nanocapsules exhibit sustained release properties for amiodarone. J Control Rel 84:59-68.
11. Lamprecht A, Saumet JL, Roux J and Benoit JP (2004) Lipid nanocarriers as drug delivery systems for Ibuprofen in pain treatment. Inti J Pharm 278(2):407-414.
12. Razzaque MS, Koji T, Kumatori A and Tagushi T (1999) Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system. Histochem Cell Biol 111:359-365.
13. Razzaque MS, Hossain MA, Ahsan N and Tagushi T (2001) Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity. Nephron 89:251-254.
14. Hossain MA, Maesaki S, Kakeya H, Noda T, Yanagihara K, Sasaki E, Hirakata Y, Tomono K, Tashiro T and Kohno S (1998) Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against cryptococcus neoformans. Antimicrob Agents Chemother 42:1722-1725.
15. Otsubo T, Maesaki S, Yamamoto Y, Tomono K, Tashiro T, Seki J, Tomii Y, Sonoke S and Kohno S (1999) In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus Fumigatus. Antimicrob Agents Chemother 43:471-475.
16. Trotta M, Cavalli R, Carlotti ME, Battaglia L and Debernardi F (2005) Solid lipid microparticles carrying Insulin formed by solvent-in-water emulsion-diffusion technique. Int J Pharm 288:281-288.
17. Zarif L (2002) Elongated supramolecular assemblies in drug delivery. J Control Rel Rev 81:7-23.
18. Zarif L, Graybill JR, Perlin D and Mannino RJ (2000) Cochleates: New lipid-based drug delivery system. J Liposome Res 10(4):523-538.
19. Papahadjopoulos D, Vail WJ, Jacobson K and Poste G (1975) Cochleate lipid cylinders: Formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 394(3):483-491.
20. Papahadjopoulos D (1978) Large unilamellar vesicles (LUV) and method of preparing the same. US Patent 4078052.
21. Papahadjopoulos D, Nir S and Duzgunes N (1990) Molecular mechanisms of calcium- induced membrane fusion. J Bioenerg Biomembr 22(2):157-179.
22. 2+ induced fusion of phospholipid vesicles monitored by mixing of aqueous contents. Nature 281(5733):690-692.
23. Mannino RJ and Gould-Fogerite S (1997) Antigen cochleate formulations for oral and systemic vaccination, in Levine MM (ed.) New Generation Vaccines. Marcel Dekker: New York, pp. 229-239.
24. Zarif L and Perlin D (2002) Amphotericin B nanocochleates: From formulation to oral efficacy. Drug Del Technol 2(3):34-37.
25. Zarif L, Graybill JR, Perlin D, Navjar L, Bocanegra R and Mannino RJ (2000) Antifungal activity of amphotericin B cochleates against Candida albicans in a mouse model. Antimi-crob Agents Chemother 44(6):1463-1469.
26. Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH and Odds FC (2000) New targets and delivery systems for antifungal therapy. Med Mycol 38(Supp 1):335-347.
27. Biodelivery Sciences: www.biodeliverysciences.com
28. Unger E (2002) Method for delivering bioactive agents using cochleates. US 6403056 B1.
29. Zarif L, Jin T, Segarra I and Mannino RJ (2001) New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules. PCT application WOOl /52817 A2.
30. Zarif L and Mannino RJ (2000) Cochleates: lipid-based vehicles for gene delivery-concept, achievements and future development, in Habib N (ed.) Cancer Gene Therapy. Past Achievements and Future Challenges. Kluwer Academic/Plenum Publishers: New York, pp. 83-94.
31. Graham I, Gagne J and Silvius JR (1985) Kinetics and thermodynamics of calcium-induced lateral phase separations in phosphatidic acid containing bilayers. Biochemistry 24(25):7123-7131.
32. Archibald DD and Mann S (1994) Self-assembled microstructures from 1,2-ethanediol suspensions of pure and binary mixtures of neutral and acidic biological galactosylceramides. Chem Phys Lipids 69(1):51-64.
33. Holland JW, Hui C, Cullis PR and Madden TD (1996) Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry 35(8):2618-2624.
34. Villardita C, Grioli S, Salmeri G, Nicoletti F and Pennisi G (1987) Multicenter clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration, Clin Trials J 24:84-93.
35. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG and Massari DC (1991) Effects of phosphatidylserine in age-associated memory impairment. Neurology 41:644-649.
36. Engle RR, Satzger W and Gunther W (1992) Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 2:149-155.
37. Amaducci L (1988) Phosphatidylserine in the treatment of Alzheimer’s disease: Results of a multicenter study. Psychopharmacol Bull 24(1):130-134.
38. Cennachi T, Bertoldin T, Farina C, Fiori MG and Crepaldi G (1993) Cognitive decline in the elderly: A double blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging 5(2):123-133.
39. Guidin J et al. (1995) Effect of soy lecithin phosphatidylserine (PS) complex on memory impairment and mood in the functioning elderly. Dept Geriatrics, Kaplan Hospital, Rehovot, Israel.
40. Maggioni M, Picotti GB, Bondiolotti GP et al. (1990) Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand 81:265-270.
41. Nerozzi D, Aceti F, Melia E, Magnani A, Marino R, Genovesi G, Amalfitano M, Cozza G, Murgiano S, De Giorgis G, et al. (1987) Phosphatidylserine and Memory Disorders in the Aged. Clin Ter 120(5):399-404.
42. Monteleone P, Beinat L, Tanzillo C, Maj M and Kemali D (1990) Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 52:243-248.
43. Monteleone P et al. (1992) Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol 41:385-388.
44. Funfgeld EW, Baggen M, Nedwidek P, Richstein B and Mistlberger G (1989) Doubleblind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Res 317:1235-1246.
45. Zarif L and Tan F (2003) Cochleates made with purified soy phosphatidylserine. US2003/0219473 Al.
46. Duzgunes N, Nir S, Wischut J, Bentz J, Newton C, Portis A and Papahadjopoulos D (1981) Calcium- and magnesium induced fusion of mixed phosphatidylserine/phosphatidylcholine vesicles: Effect of ion-binding. J Membr Biol 59:115-125.
47. Portis A, Newton C, Pangborn W and Papahadjopoulos D (1979). Studies on the mechanism of membrane fusion: Evidence for an intermembrane Ca2+-phospholipid complex, synergism with Mg2+, and inhibition by spectrin. Biochemistry 18:780-790.
48. Santangelo R, Paderu P, Delmas G, Chen ZW Mannino R, Zarif L and Perlin D (2000) Efficacy of oral cochleates amphotericin b in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 44(9):2356-2360.
49. Zarif L, Segarra I, Jin T, Scolpino A, Hyra D, Daublin P, Krause S, Perlin DS, Lambros C, Graybill JR and Mannino RJ (1999) Lipid-based cochleate system for oral and systemic delivery of drugs. AAPS Eastern Regional Meeting and Exposition.
50. Segarra I, Hyra-Movshin DA, Chen ZW, Santangelo R, Perlin D, Paderu P, Mannino RJ and Zarif L (2000) AmB Cochleates, a new lipid-based formulation for amphotericin B: From IV pharmacokinetics to oral efficacy. Millenial World Congress of Pharmaceutical Sciences, San Franscisco, CA, April, pp. 124.
51. Segarra I, Jin T, Hyra D, Mannino RJ and Zarif L (1999) Oral administration of amphotericin B with a new AmB-cochleate formulation: Tissue distribution after single and multiple oral dose. ICAAC 39:Abs 1940.
52. Segarra I, Movshin D, Mannino RJ and Zarif L (2000) Pharmacokinetics and tissue distribution of amphotericin B in Mice after oral administration of AmB cochleates, a new effective lipid-based formulation for the oral treatment of systemic fungal infections. ICAAC 40:Abs 861.
53. Segarra I, Chen ZW, Movshin DA, Tan F, Mannino RJ and Zarif L (2000) Tissue distribution of oral amphotericin B lipid-based cochleate formulation: Comparison with AmBisome. 27th International Symposium on Controlled Release of Bioactive Materials, Paris France, pp. 67-68.
54. Zarif L, Segarra I, Jin T, Hyra D and Mannino RJ (1999) Amphotericin B cochleates as a novel oral delivery system for the treatment of fungal infections. 26th International Symposium on Controlled Release of Bioactive Materials. Boston, MA, June 20-23.
55. Perlin D, Santangelo R, Mannino R and Zarif L (2000) Oral delivery of cochleates containing amphotericin B (CAMB) is highly effective in a candidiasis murine model, Focus Fungal Infect.
56. Zarif L, Segarra I, Jin T, Hyra D, Perlin D, Graybill JR and Mannino JR (1999) Oral and systemic delivery of amphotericin B mediated by cochleates. AAPS Annual Meeting and Exposition, November.
57. Zarif L, Jin T, Scolpino A and Mannino RJ (1999) Are cochleates the new lipid-based carrier for oral drug delivery? 39th ICAAC, San Francisco, CA, September 26-29.
58. Delmas G, Perlin D, Chen ZW and Zarif L (2001) Amphotericin B cochleates: Evaluation for the oral treatment of aspergillosis in murine model, The 28th International Symposium of Controlled Release of Bioactive Materials, San Diego, CA, June 23-29, pp. 433-434.
59. Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L and Perlin DS (2002) Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 46(8):2704-2707.
60. Graybill JR, Navjar L, Bocanegra R, Scolpino A, Mannino RJ and Zarif L (2000) A new lipid vehicle for amphotericin B, Abstract, 39th ICAAC, San Franscisco, CA, September, Abs 583.
61. Delmarre D, Lu R, Taton N, Krause-Elsmore S, Gould-Fogerite S and Mannino RJ (2004) Cochleate-mediated delivery: Formulation of hydrophobic drugs into cochleate delivery vehicles: A simplified protocol & bioral formulation kit. Drug Del Techno 4(1):64-69.
62. Ramani K and Balasubramanian S (2003) Fluorescence properties of Laurdan in cochleate phases. Biochim Biophys Acta 1618(1):67-78.
63. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE and Edwards JE (2000) Practice guidelines for the management of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30(4):662-678.
64. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD and Dismukes WE (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30(4):710-718.
65. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Dening DW, Bennett JE, Walsh TJ, Patterson TF and Pankay GA (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30(4):696-709.
66. Hiemenz JW and Walsh TJ (1996) Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 22(Suppl 2):133-144.
67. Graybill JR, Najvar LK, Bocanegra R, Scolpino A, Mannino RJ and Zarif L (1999). Cochleate: A new lipid vehicle for amphotericin B. ICAAC 39:Abs 2009.
68. Zarif L, Graybill J, Najvar L, Perlin D and Mannino RJ (2000) Amphotericin B cochleates: Novel lipid-based drug delivery system for the treatment of systemic fungal infections., 14th ISHAM World Congress, May 8-12, Buenos Aires, Argentina.
69. Segarra I, Movshin DA and Zarif L (2002) Extensive tissue distribution of amphotericin B after intravenous administration in cochleate vehicle to mice. 29th International Symposium on Controlled Release of Bioactive Materials, Seoul, Korea.
70. Segarra I, Movshin D and Zarif L (2002) Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. J Pharm Sci 91(8):1827-1837.
71. Legrand P, Vertut-Doi A and Bolard J (1996) Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 37:519-533.
72. Bratosin D, Mazurier J, Tissier JP, Slomianny C, Estaquier J, Russo-Marie F, Huart JJ, Freyssinet JM, Aminoff D, Ameisen JC and Montreuil J (1997) Molecular mechanism of erythrophagocytosis. Characterization of the senescent erythrocytes that are phagocytized by macrophages. CR Acad Sci Paris Sciences de la Vie/Life Sci 320:811-818.
73. Popescu C, Adams L, Franzblau S and Zarif L (2001) Cochleates potentiate the efficacy of the antimycobacterial drug, clofazimine. ICAAC 41:Abs 2278.
74. Jin T (2003) Cochleates without metal cations as bridging agents. US Patent application 10/636,522.
75. Slayton W, Anstine D, Lakhdir F, Sleasman J and Neiberger R (1996) Tetany in a child with AIDS receiving intravenous tobramycin. South Med J 89:1108-1110.
76. Keating MJ, Sethi MR, Bodey GP and Samaan NA (1977) Hypocalcemia with hypopara thyroidism and renal tubular dysfunction associated with aminoglycoside therapy. Cancer 39:1410-1414.
77. RRC (1990) New (Ed.), Liposomes, a practical approach, IRL Press, Oxford University Press, New York.
78. Gould-Fogerite S, Mazurkiewicz JE, Raska K Jr, Voelkerding K, Lehman JM and Mannino RJ (1989) Gene 84(2):429-438.
79. Perez O, Brach G, Lastre M, Mora N, Del Campo J, Gil D, Zayas C, Acevedo R, Gonzales D, Lopez J, Taboada C and Solis RL (2004) Novel adjuvant based on a proteoliposome-derived cochleate structure containing native polysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol 82(6):603-610.